Century Therapeutics files financials of acquired Clade; Clade had $38.6M net loss in 2023

Century Therapeutics, Inc.

Clade's audited FY2023 net loss $38.6M, accumulated deficit $51.8M as of Dec 31, 2023.
Clade had $14.2M cash at year-end 2023; going concern doubt noted for next 12 months.
Unaudited pro forma combined financials for FY2023 filed; acquisition closed April 11, 2024.
No deal value disclosed in this amendment; prior 8-K on April 11 announced acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.